Current Cardiovascular Risk Reports

, Volume 6, Issue 3, pp 205–209 | Cite as

Postmenopausal Hormone Therapy: Does It Have a Role in Cardiovascular Prevention Today?

Women and Cardiovascular Disease (J Robinson, Section Editor)


Cardiovascular disease is the leading cause of mortality in women. Results from observational studies consistently demonstrated lower heart disease rates among women who used hormone replacement therapy (HRT) compared to non-users. Data from two large randomized controlled trials showed mixed results. Subsequent post-hoc analysis found cardiovascular disease among HRT users to be lower than non-users in women 50 to 59 years of age or less than 10 years post-menopause. This has sparked much debate on the role of postmenopausal hormone therapy, especially in peri-menopausal women. Two hypotheses have been suggested to explain this divergent data: 1) HRT may be cardioprotective when introduced prior to atherosclerosis development but may be harmful in women with established CVD; or 2) HRT may be useful when started closer to menopause initiation and harmful when started later in life.


Hormone replacement therapy Cardiovascular disease Coronary artery disease Stroke Menopause Coronary artery calcium 


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    National Vital Statistics Reports. Volume 58, Number 19 May 20, 2010
  2. 2.
    Global atlas on cardiovascular disease prevention and control.
  3. 3.
    Heart Disease and Stroke Statistics--2012 Update: A Report From the American Heart Association.
  4. 4.
    Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system. J Am Coll Cardiol. 2006;47:1741–53.PubMedCrossRefGoogle Scholar
  5. 5.
    Gordon T, Kannel WB, Hjortland MC, et al. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978;89:157–61.PubMedGoogle Scholar
  6. 6.
    • Aging, menopause, cardiovascular disease and HRT. International Menopause Society Consensus Statement. Climacteric 2009;12:368–77. This paper is a consensus statement on cardiovascular aspects on menopause and available treatments written by international experts. Google Scholar
  7. 7.
    Colditz GA, Willet WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105–111.PubMedCrossRefGoogle Scholar
  8. 8.
    Harman SM, Vittinghoff E, Brinton ES, et al. Timing and duration of menopausal hormone treatment may effect cardiovascular outcomes. Am J Med. 2001;124:199–205.CrossRefGoogle Scholar
  9. 9.
    • Estrogen and progesterone use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17:242–55. This position statement aims to clarify the risks and benefits of hormone replacement therapy for prevention and treatment of menopause-related symptoms. Google Scholar
  10. 10.
    Collins P, Shay J, Jiang C, et al. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation. 1994;90:1964–8.PubMedGoogle Scholar
  11. 11.
    Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. Journal of American Medical Association 1995 Jan 18;273:199–208.Google Scholar
  12. 12.
    Suzuki S, Brown CM, Dela Cruz CD, et al. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neurooprotective and anti-inflammatory actions. Proc Natl Acad Sci U S A. 2007;104:6013–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292:1573–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Canonico M, Plu-Bureau G, Lowe GD, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. British Medical Journal. 2008;336:1227–31.PubMedCrossRefGoogle Scholar
  15. 15.
    Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933–41.PubMedGoogle Scholar
  16. 16.
    Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestion for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349:535–45.PubMedCrossRefGoogle Scholar
  19. 19.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med. 2006;166:357–66.PubMedCrossRefGoogle Scholar
  21. 21.
    Clarkson TB. Progestogens and cardiovascular disease. A critical review. Journal of Reproductive Medicine. 1999;44:180–4.Google Scholar
  22. 22.
    Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–77.PubMedCrossRefGoogle Scholar
  23. 23.
    Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkey. J Clin Endocrinol Metab. 1998;83:721–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Williams JK, Anthony MS. Regression of atherosclerosis in female monkey. Arterioscler Thromb Vasc Biol. 1995;15:827–36.PubMedCrossRefGoogle Scholar
  25. 25.
    Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. Ann Intern Med. 2001;135:939–53.PubMedGoogle Scholar
  26. 26.
    Rosenfeld ME, Kauser K, Martin-McNulty B. Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice. Atherosclerosis. 2002;164:251–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Hu P, Greendale GA, Palla SL, et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix mettaloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis. 2006;185:347–52.PubMedCrossRefGoogle Scholar
  28. 28.
    McLaughlin VV, Hoff JA, Rich S. Relation between hormone replacement in women and coronary artery disease estimated by electron beam tomography. Am Hear J. 1997;134:1115–9.CrossRefGoogle Scholar
  29. 29.
    Shemesh J, Frenkel Y, Leibovitch L, et al. Does hormone replacement therapy inhibit coronary artery calcification? Obstet Gynecol. 1997;89:989–92.PubMedCrossRefGoogle Scholar
  30. 30.
    Hecht HS, Budoff MJ, Berman DS, et al. Coronary artery calcium scanning: clinical paradigms for cardiac risk assessment and treatment. Am Hear J. 2006;151:1139–46.CrossRefGoogle Scholar
  31. 31.
    Budoff MJ, Chen GP, Hunter CJ, et al. Effects of hormone replacement on progression of coronary calcium as measured by electron beam tomography. Journal of Women’s Health. 2005;14:410–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary artery calcification. N Engl J Med. 2007;356:2591–602.PubMedCrossRefGoogle Scholar
  33. 33.
    • Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of American College of Cardiology 2010;56:e50–103. This guideline published by the American College of Cardiology shows how to risk stratify patients with no known CAD. Google Scholar
  34. 34.
    Harman SM, Brinton EA, Cedars M, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric. 2005;8:3–12.PubMedCrossRefGoogle Scholar
  35. 35.
    ELITE: Early versus Late Intervention Trial with Estradiol. Bethesda, MD: National Institute of Aging, 2007.
  36. 36.

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterTorranceUSA

Personalised recommendations